Core Viewpoint - KDventures AB has announced a directed issue of 5,283,870 series B shares to compensate guarantors for their commitments related to a rights issue, deviating from shareholders' preferential rights [2][3]. Group 1: Directed Issue Details - The directed issue will increase the company's share capital by up to SEK 52,838.70 [3]. - The subscription price for the directed issue is set at SEK 0.31 per share, based on the volume-weighted average price during the rights issue subscription period [4]. - The total claims of the guarantors against the company amount to SEK 1,638,000, which will be settled through the issuance of new shares [4]. Group 2: Impact on Share Capital - After the registration of the directed issue, the total number of series B shares will reach 656,972,867, and the company's total share capital will be SEK 6,595,281.28 [4]. - The dilution effect from this directed issue is approximately 0.8 percent [4]. Group 3: Company Overview - KDventures AB is a Nordic investment company focused on life sciences, investing in innovative pharmaceutical projects and medical technology products from leading research institutions in the Nordic region [7]. - The company aims to create value through a diversified portfolio and active engagement in various stages of development, offering investors exposure to both listed and private life science projects with significant growth potential [7].

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH KOREA, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO, OR INVITATION TO, ACQUIRE OR SUBSCRIBE FOR ANY SECURITIES IN KAROLINSKA DEVELOPMENT AB (PUBL) IN ANY JURISDICTION. PLEASE ALSO REFER TO THE SECTION “IMPORTANT ...

Core Viewpoint - Karolinska Development AB has announced additional guarantee commitments of approximately 20 MSEK in its ongoing rights issue, bringing the total to approximately 115.2 MSEK, which covers about 57% of the rights issue volume [2][3]. Group 1: Rights Issue Details - The rights issue was resolved by the Board of Directors on December 1, 2025, and approved by the extraordinary general meeting on January 8, 2026, with a subscription period running until January 27, 2026 [2]. - The total rights issue amount is approximately 202.6 MSEK before issue costs [2]. - The Intermediate Guarantee covers the interval from approximately 47% to 57% of the rights issue, amounting to approximately 115.2 MSEK [3]. Group 2: Guarantee Commitments - Previously agreed guarantee commitments have increased from approximately 95.2 MSEK to approximately 115.2 MSEK [3]. - The guarantee commitments are not secured through bank guarantees or similar arrangements [5]. - A cash guarantee fee of 13% or a fee of 15% in newly issued shares will be paid for the Intermediate Guarantee [4]. Group 3: Shareholder Implications - Investors acquiring a shareholding of 10% or more of the total votes in the Company must notify the Inspectorate of Strategic Products prior to the investment [6]. - Any guarantee commitments that require approval under the Swedish Screening of Foreign Direct Investments Act are conditional upon obtaining such approval [6][19]. Group 4: Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing medical innovations [10]. - The company aims to build companies around leading scientists and management teams, co-funded by international investors [11]. - Karolinska Development has a portfolio of eleven companies targeting innovative treatments for serious diseases [12].

Core Viewpoint - Karolinska Development AB is initiating a rights issue to raise approximately SEK 202.6 million for the continued development of existing investments and general corporate purposes [2][6]. Rights Issue Details - The rights issue involves a maximum of 675,193,985 series B shares at a subscription price of SEK 0.30 per share [6]. - The subscription period runs from January 13, 2026, to January 27, 2026, with trading in subscription rights occurring from January 13 to January 22, 2026 [4][6]. - Shareholders holding series A and B shares will have preferential rights to subscribe, with one existing share granting five subscription rights, and two subscription rights allowing the purchase of one new series B share [6]. Financial Commitments - Prior to the rights issue, the company has secured subscription undertakings from its Board of Directors and management amounting to approximately SEK 5.2 million, representing about 2.6% of the rights issue [6]. - Additionally, the company has entered into guarantee commitments totaling approximately SEK 95.2 million, which is about 47% of the rights issue, including the subscription undertakings [6]. Timeline and Trading Information - The estimated date for announcing the outcome of the rights issue is around January 29, 2026, with trading in new shares expected to commence on February 16, 2026 [4][6]. - Trading in paid subscribed shares (BTA) will occur from January 13, 2026, until around February 12, 2026 [4]. Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing breakthrough medical innovations [10]. - The company aims to build companies around leading scientists and management teams, co-funded by international investors, to enhance the chances of success in advancing medical innovations [11]. - The company has a portfolio of eleven companies targeting innovative treatments for serious diseases [12].

Core Viewpoint - Karolinska Development AB is conducting a rights issue of series B shares amounting to approximately SEK 202.6 million, which has been approved by the Board of Directors and the extraordinary general meeting [2]. Group 1: Rights Issue Details - The rights issue is set to raise approximately SEK 202.6 million before transaction costs, as resolved by the Board on December 1, 2025, and approved on January 8, 2026 [2]. - An information document has been prepared in accordance with the Prospectus Regulation, detailing the terms and conditions of the rights issue, which has been registered with the Swedish Financial Supervisory Authority [3]. - The timetable for the rights issue includes trading in subscription rights from January 13 to January 22, 2026, and a subscription period from January 13 to January 27, 2026 [4]. Group 2: Advisory and Legal Support - Redeye AB is acting as the financial adviser, while Cirio Advokatbyrå AB serves as the legal adviser for the rights issue [5]. Group 3: Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing breakthrough medical innovations in the Nordic region [7]. - The company aims to create and grow companies that advance medical innovations into commercial products, benefiting patients and providing returns to shareholders [8]. - Karolinska Development has access to world-class medical innovations from leading universities and research institutes, aiming to build companies around top scientists supported by experienced management teams [9].

Core Viewpoint - Karolinska Development AB held an Extraordinary General Meeting on January 8, 2026, where significant resolutions were made regarding share capital increase and company name change [1]. Group 1: Share Capital Increase - The Board of Directors' resolution to issue new shares with preferential rights for existing shareholders was approved, allowing an increase in share capital by up to SEK 6,751,939.85 through a rights issue of no more than 675,193,985 shares of series B [2]. - Each existing share entitles shareholders to five subscription rights, with two subscription rights allowing the subscription of one new share of series B at a price of SEK 0.30 per share [3]. Group 2: Subscription Period - The subscription period for the rights issue is set from January 13, 2026, to January 27, 2026 [4]. Group 3: Amendments to Articles of Association - The company name will be changed to KDventures AB, and amendments were made to the object of the Company's business, with share capital limits set between SEK 2,650,000 and SEK 10,600,000, and the number of shares limited to between 265,000,000 and 1,060,000,000 [5]. Group 4: Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing breakthrough medical innovations in the Nordic region [8]. - The company has access to world-class medical innovations from leading universities and research institutes, aiming to build companies around leading scientists supported by experienced management teams [9]. - Karolinska Development has a portfolio of eleven companies targeting innovative treatments for serious diseases, led by a team of investment professionals with a strong track record [10].

Core Viewpoint - Karolinska Development AB held its Annual General Meeting on May 15, 2025, where several key resolutions were passed regarding financial statements, board composition, remuneration, and authorizations for share transactions and new issues of shares [1][2][3][4][5][9][10]. Financial Resolutions - The profit and loss statement and balance sheet for the financial year 2024 were adopted, with a total of SEK 1,235,972,877 to be carried forward [1][2]. - The Board of Directors' remuneration report for 2024 was approved in accordance with Swedish regulations [8]. Board Composition and Remuneration - The number of directors was set to five without deputies, and one auditor was appointed without a deputy [3]. - The chairman will receive a fixed remuneration of SEK 400,000, while other directors will receive SEK 200,000, both paid in proportion to board meetings attended [4]. - Ben Toogood was re-elected as Chairman of the Board, and four other directors were re-elected, with Anders Härfstrand newly elected [5]. Nomination Committee - A Nomination Committee consisting of five members was established, appointed by the five largest shareholders based on voting power [6][7]. - The committee is responsible for proposing candidates for the Board of Directors and auditor, as well as evaluating its own instructions annually [7]. Shareholder Authorizations - The Board of Directors was authorized to transfer all shares of series B held by the Company, with transfers to occur on Nasdaq Stockholm or otherwise, at market terms [9]. - The Board was also authorized to issue new shares of series B up to 20% of the total share capital, with conditions to ensure compliance with the Company's maximum allowed share capital [10].